CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose
CPX-351 at 44 mg/m<sup>2</sup> daunorubicin/dose was safe and tolerable in children with R/R acute leukemia, showing promising activity in heavily pretreated, high-risk AML and is now the FDA-approved pediatric dose for therapy-related AML or AML with myelodysplastic changes.
Authors
- Erin H. Breese (ORCID: https://orcid.org/0000-0002-4435-3217)
- Jonathan D. Bender (ORCID: https://orcid.org/0000-0003-0586-2411)
- C.U. Blank
- Lori R. Backus
- Benjamin Mizukawa (ORCID: https://orcid.org/0000-0002-3312-2982)
- Michael J. Absalon
- Lauren Pommert (ORCID: https://orcid.org/0000-0001-8760-5202)
- Karen Burns (ORCID: https://orcid.org/0000-0002-7296-4226)
- Robin Elizabeth Norris (ORCID: https://orcid.org/0000-0002-8589-1804)
- J. V. I. Young
- John P Perentesis
- Maureen M O'Brien
- Adam Lane
- Thomas D. Ryan
- Daniel Peck
- Christine Phillips
- Lynn H. Lee
- Andrea Bidwell
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- Oregon Health & Science University (US)
- Children's Hospital Colorado (US)
- University of Minnesota Children's Hospital (US)
- University of Cincinnati Medical Center (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1002/1545-5017.70268
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00